drugset / Trial / NCT00191373
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |